Protocol Ledger

Academic / Institutional Sponsor · Consolidated Sponsor Hub

University of Birmingham: Clinical Trials & FDA Approval Profile

University of Birmingham (Global / Institutional) sponsors 25 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 13 active protocols (9 recruiting now), 5 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)12.0%
Median Closed Enrollment vs National (145 pts)49 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for University of Birmingham
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)25
Active Pipeline (Recruiting Now)13 (9)
Completed vs Stopped Early5 / 3 (12.0%)
Median Closed Actual Enrollment49 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With University of Birmingham
Hospital Research SiteLocationShared Protocols
Leicester Royal InfirmaryLeicester6
University Hospital of WalesCardiff, Wales5
Derriford HospitalPlymouth, Devon5

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by University of Birmingham
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT05848765Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapyPhase IIRECRUITING
NCT04888741Methods of T Cell Depletion Trial (MoTD)Phase IIRECRUITING
NCT04116502MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia VeraPhase IIIRECRUITING
NCT05991388A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin LymphomaPhase II/IIIRECRUITING
NCT04256798Perioperative Respiratory Care and Outcomes for Patients Undergoing High Risk Abdominal SurgeryPhase IIIRECRUITING

Explore interactive annual charts and M&A subsidiary rollups in the University of Birmingham Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI